# A Study of Safety, Tolerability, and Pk of rhMBL in Pediatric Hematology/Oncology Pts With Fever and Neutropenia

> **NCT00520325** · PHASE1 · WITHDRAWN · sponsor: **Enzon Pharmaceuticals, Inc.**

## Conditions studied

- Cancer
- Hematologic Diseases
- Fever
- Neutropenia

## Interventions

- **DRUG:** Intravenous recombinant human mannose binding lectin
- **DRUG:** Intravenous recombinant human mannose binding lectin

## Key facts

- **NCT ID:** NCT00520325
- **Lead sponsor:** Enzon Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2007-06
- **Primary completion:** 2009-06
- **Final completion:** 2009-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor decision to terminate the study
- **Last updated:** 2012-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00520325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00520325, "A Study of Safety, Tolerability, and Pk of rhMBL in Pediatric Hematology/Oncology Pts With Fever and Neutropenia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00520325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*